

Figure S1




Figure S1. Focal cholangiocellular differentiation within NRAS induced HCC

Tumour with overall HCC morphology and central focus of cholangiocellular differentiation as indicated by positivity for CK7 and reduction of hepatocellular marker CPS1. The high proliferation index within this region confirms its neoplastic nature. Representative image of an occasional observation. *Scale bar*: 100 μ m.

Figure S2




Figure S2. Extended immunohistochemical analysis of *NRAS*^{G12V} induced neoplastic lesions

Preneoplastic lesions (upper panel) and a tumour (lower panel) analysed with the indicated antibodies. *Scale bar*: 100 μ m / inset 50 μ m.

Figure S3




Figure S3. Western blots of selected target proteins in human HCC cell lines.

Western blot analysis of indicated HCC cell lines. Molecular weights of observed bands are marked on the right. Note that an *NRAS* Q61K mutation is present in SNU-387 and Hep-G2 carries an *NRAS* Q61L mutation, while the other cell lines are *NRAS* wildtype according to the Cancer Cell Line Encyclopedia (Broad, 2019). Cropped images of Western Blots are shown. The full images of the hybridised cut membranes are included in Figure S7.

Figure S4





Figure S4. NanoString® gene expression analysis of AKT Cre/NRAS versus AKT/NRAS mouse liver cancer cell lines

Volcano plot of differentially expressed genes obtained from NanoString® mRNA measurement using the mouse Pan Cancer pathway panel®.

Figure S5

a



b




Figure S5. Confirmation of silencing effectiveness for xCELLigence® proliferation experiments

(a) Western blot analysis of AKT Cre/ NRAS cell line treated with indicated siRNA or SCR. Molecular weights of observed bands are marked on the right. Cropped images of Western Blots are shown. The full images of the hybridised cut membranes are included in Figure S7.

(b) Quantitative real-time PCR analyses of PLC treated with indicated siRNA or SCR. Taqman® probes for DUSP4 on left and DUSP6 on right. Error bars indicate 95% confidence interval.

Figure S6




Figure S6. NRAS transfection to CCA cell line

Representative Western blot analysis of NRAS^{G12V} transfection to RAS wild type CCA cell line KKU-M055. Molecular weights of observed bands are marked on the right. Quantification of protein levels of DUSP4 and DUSP6 from 2 repeats with 3 replicates each on the right. Mean with standard deviation. Asterisk indicates $p < 0.05$ (Mann-Whitney-U Test). Cropped images of Western Blots are shown. The full images of the hybridised cut membranes are included in Figure S7.

Figure S7_1

Corresponds to Figure 2b





Figure S7. Uncropped Western blots

Uncropped pictures of all Western Blots as shown in the article's figures, including all data from repeats and replicates. Antibody hybridisation was performed on already cut membranes to economise on resources. Occasional lateral cropping means that other samples have been run on the same blot, which are irrelevant to this paper and its conclusions.


Figure S7_2

Corresponds to Figure 4c


DUSP4



DUSP6



CD133



Beta actin



Figure S7_3

Corresponds to Figure 5a




Figure S7_4

Corresponds to Figure 5b

DMSO 2 μ M 30
1 min
TPA 0.5 μ M 30
2 min
3 TPA 2 μ M 30 min
DMSO 2 μ M 60
4 min
TPA 0.5 μ M 60
5 min
6 TPA 2 μ M 60 min

PLC

HUH-7

SNU-182


1 1 1 2 2 3 3 3 4 4 4 5 5 6 6 6

4 5 6 4 5 6 4 5 6


4 5 6 4 5 6 4 5 6

DUSP4


38 kDa



38 kDa




38 kDa




DUSP6


38 kDa



38 kDa




38 kDa




pERK 1/2

38 kDa



38 kDa




38 kDa




ERK 1/2


38 kDa



38 kDa




38 kDa




beta-actin

38 kDa



38 kDa



38 kDa





Figure S7_5

Corresponds to Figure 5c

a



Corresponds to Figure 5d

b




Figure S7_6

Corresponds to Figure 6a



AKT/NRAS SCR Replicate1
AKT / NRAS DUSP4 siRNA Replicate1
AKT/NRAS SCR Replicate 2
AKT / NRAS DUSP4 siRNA Replicate2
AKT/NRAS SCR Replicate 3
AKT / NRAS DUSP4 siRNA Replicate3
AKT Cre / NRAS SCR Replicate1
AKT Cre / NRAS DUSP4 siRNA Replicate1
AKT Cre / NRAS SCR Replicate 2
AKT Cre / NRAS DUSP4 siRNA Replicate2
AKT Cre / NRAS SCR Replicate 3
AKT Cre / NRAS DUSP4 siRNA Replicate3

AKT Cre/NRAS SCR Replicate1
AKT Cre / NRAS DUSP4 siRNA Replicate1
AKT Cre/NRAS SCR Replicate 2
AKT Cre / NRAS DUSP4 siRNA Replicate2
AKT Cre/NRAS SCR Replicate 3
AKT Cre / NRAS DUSP4 siRNA Replicate3
AKT/NRAS SCR Replicate1
AKT / NRAS DUSP4 siRNA Replicate1
AKT/NRAS SCR Replicate 2
AKT / NRAS DUSP4 siRNA Replicate2
AKT/NRAS SCR Replicate 3
AKT / NRAS DUSP4 siRNA Replicate3


Repeat 1

Repeat 2


pERK1/2





ERK1/2





DUSP4



DUSP6



CD133



Beta-actin





Figure S7_7 Corresponds to Figure 7a





Figure S7_8 Corresponds to Figure S3

HLE HLF HUH7 Hep3b SK-HEP-1 PLC/PRF15 MHCC97-L SNU-449 SNU-182 SNU-387 Hep-G2 HuH6


pERK 1+2




ERK 1/2




CD133



DUSP4



DUSP6



NRAS



Beta-actin



Figure S7_9 Corresponds to Figure S5a






Figure S7_10 Corresponds to Figure S6


DUSP4



DUSP6



NRAS



Beta-actin

